Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 2/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406488 | 1.00 | IDO1 (0.38) | IDO1MAOBAPPKMT2ANPC1 | |
| SCHEMBL481295 | 0.81 | IDO1 (0.47) | IDO1MAOBAPPKMT2ANPC1 | |
| SCHEMBL2408911 | 0.81 | LPL (0.39) | KMT2ACA1CA2HTT | |
| SCHEMBL2408912 | 0.81 | LPL (0.39) | KMT2ACA1CA2HTT | |
| SCHEMBL1013889 | 0.80 | IDO1 (0.42) | IDO1MAOBAPPKMT2ACA1 | |
| SCHEMBL556155 | 0.80 | IDO1 (0.42) | IDO1MAOBAPPKMT2ACA1 | |
| SCHEMBL2408881 | 0.77 | IDO1 (0.42) | IDO1MAOBAPPKMT2ACA1 | |
| SCHEMBL2408874 | 0.77 | IDO1 (0.42) | IDO1MAOBAPPKMT2ACA1 | |
| SCHEMBL2405469 | 0.73 | IDO1 (0.45) | IDO1MAOBAPPKMT2ARAB9A | |
| SCHEMBL2405472 | 0.73 | IDO1 (0.45) | IDO1MAOBAPPKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212950-A1 | 4,4-DISUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212950-A1 | 4,4-DISUBSTITUTED PIPERIDINES | REN, AGTR2, AVPR2 | IDO1 3753/4885MAOB 891/4885APP 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.